Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes

Pharmacogenetics

Volumn 10, Issue 3, 2000, Pages 267-270

  Miners, John O ^a   Coulter, Sally ^a   Birkett, Donald J ^a   Goldstein, Joyce A ^b  

^a FLINDERS MEDICAL CENTRE   (Australia)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

CYP2C9; Cytochrome P450; Polymorphism; Sulphaphenazole inhibition; Torsemide

Indexed keywords

CYTOCHROME P450 2C9; CYTOCHROME P450 ISOENZYME; HYMECROMONE; RECOMBINANT ENZYME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TORASEMIDE;

ACCURACY; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MICHAELIS CONSTANT; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE;

SACCHAROMYCES CEREVISIAE;

EID: 0034104053     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200004000-00008     Document Type: Article

References (19)

1. Aithal GP, Day CP, Kesteven PJL, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dosage requirement and risk of bleeding complications. Lancet 1999; 353:717-719.
2. Bhasker CR, Miners JO, Coulter S, Birkett DJ. Allelic and functional variability of cytochrome P4502C9. Pharmacogenetics 1997; 7:51-58.
3. Holford NHG. MK Model: a modelling tool for microcomputers. Pharmacokinetic evaluation and comparison with standard computer programs. Clin Exp Pharmacol Physiol 1985. 9(suppl):95.
4. Ibeanu GC, Ghanayem BI, Linko P, Li L, Pedersen LG, Goldstein JA. Identification of residues 99, 220, and 221 of human cytochrome P450 2C19 as key determinants of omeprazole hydroxylase activity. J Biol Chem 1996; 271:12496-12501.
5. Ibeanu GC, Blaisdell JA, Ferguson RJ, Ghanayem BI, Brosen K, Benhamou S, et al. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metaboliser phenotype of the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Ther 1999; 290:635-640.
6. Kidd RS, Straughn AB, Meyer MC, Blaisdell J, Goldstein JA. Dalton JT. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics 1999; 9:71-80.
7. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45:525-538.
8. Miners JO, Wing LMH, Birkett DJ. Normal metabolism of debrisoquine and theophylline in a slow tolbutamide metaboliser. Aust N Z J Med 1985; 15:348-349.
9. Miners JO, Smith KJ, Robson RA, McManus ME, Veronese ME, Birkett DJ. Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P450 dependent xenobiotic oxidations. Biochem Pharmacol 1988; 37:1137-1144.
10. Miners JO, Rees DLP, Valente L, Veronese ME, Birkett DJ. Human hepatic cytochrome P450 2C9 catalyses the rate-limiting pathway of torsemide metabolism. J Pharmacol Exp Ther 1995; 272:1076-1081.
11. Nasu K, Kubota T, Ishizaki T. Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics 1997; 7:405-409.
12. Odani A, Hashimoto Y, Otsuki Y, Uwai Y, Hattori H, Furusho K, et al. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clin Pharmacol Ther 1997; 62:287-292.
13. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994; 4:39-42.
14. Spielberg S, McCrea J, Cribb A, Rushmore TM, Waldman S, Bjornsson T, et al. A mutation in CYP2C9 is responsible for decreased metabolism of losartan. Clin Pharmacol Ther 1996; 59:215.
15. Steward DJ, Haining RL, Henne KR, Davis G, Rushmore TH, Trager WF, et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 1997; 7:361-367.
16. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 1996; 6:429-439.
17. 359 variant in the tolbutamide polymorphism. Pharmacogenetics 1996, 6:341-349.
18. 359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics 1998; 8:365-373.
19. Wang S-L, Huang J-D, Lai M-D, Tsai J-J. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 1995; 5:37-42.